Tagged with Lilly

India The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis drug baricitinib, Zydus Cadila’s upcoming approval of its COVID-19 vaccine, and the emergency use authorization for a COVID-19 antibody drug…

Coronavirus During the fourth International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) COVID-19 media briefing, one thematic dominated: collaboration. With Eli Lilly chairman and CEO David Ricks, also president of IFPMA; Roche CEO Dr Severin Schwan, also vice-president of IFPMA; Pfizer chairman and CEO Dr Albert Bourla; MSD (Merck & Co.…

China The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly has struck a deal for the exclusive license of Innovent’s TYVYT® drug outside of China stands to catapult the Chinese…

China Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on the Hong Kong Stock Exchange and their first product, toripalimab, being the first anti-PD-1 monoclonal antibody self-developed by a Chinese…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…

Coronavirus During a global virtual press briefing on 19 March 2020, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) gathered five global pharmaceutical leaders including Eli Lilly Chairman and CEO David A. Ricks, who is also the president of IFPMA for 2019-2020, to discuss the global ramifications of the COVID-19…

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…

UAE Eli Lilly’s president and general manager for the SAMETA (South Asia, Middle East, Turkey, and Africa) region, José Antonio Alas, discusses the challenges attached to overseeing 70 countries and half of the world’s population, the main opportunities for Lilly’s diabetes and oncology portfolio in the region, and the importance of…

Czech Republic Miha Kline has been with Eli Lilly for the past 15 years, becoming Country Manager Czech Republic and Slovakia four years ago. Kline shares his milestones with the affiliate successfully entering new therapeutic areas and reaching 1bn CZK in sales. Kline also discusses the challenging market access conditions and the…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…